Study of Papillex4 Dietary Supplement for Treating Abnormal Cervical Cells Caused by HPV in Women Ages 25 to 55

What this Trial Is About

Researchers are evaluating the safety and effectiveness of Papillex4, a dietary supplement, in women diagnosed with cervical intraepithelial neoplasia CIN grades 1 or 2 caused by HPV infection. The study aims to determine whether Papillex4 leads to regression of abnormal cervical cells compared to a placebo over a 180-day period. This randomized, triple-blind, placebo-controlled trial focuses on cervical cell changes confirmed by histology or cytology. Participants will take either Papillex4 or a placebo, each given as two capsules twice daily with food, one dose with the first meal and one with the last meal. The supplement contains various vitamins and natural extracts. The treatment period lasts 180 days, during which participants also complete questionnaires and undergo tests including a PAP smear, HPV testing, and colonoscopy if applicable. Throughout the study, participants are asked to maintain their usual lifestyle habits and attend clinic visits for sample collection and assessments. Researchers will monitor changes in cervical cell status, HPV clearance, immune markers, micronutrient levels, symptom scores, and quality of life measures up to 360 days. Safety is assessed by tracking adverse events during and after the treatment period, with study completion expected by December 2026.

A Clinical Trial to Investigate the Safety and Efficacy of Papillex® on Abnormal Cervical Cells Caused by HPV.